Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artelo BiosciencesARTL +4.06%32 3-Year FCF Growth Rate is 21.90% as of Jun. 2026, which is at its 10-year median of 21.90. GuruFocus rates ARTL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,103 Biotechnology companies, Artelo Biosciences ranks better than 53.67% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 31.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Artelo Biosciences was 52.10% per year. The lowest was -115.60% per year. And the median was 21.90% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Artelo Biosciences 3-Year FCF Growth Rate Related Terms
ARTL vs PPCB, CLDI, GNPX: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Artelo Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 21.90% mean?
Artelo Biosciences (ARTL) has a 3-Year FCF Growth Rate of 21.90% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Artelo Biosciences and its competitors. This is near median its historical median of 21.90. According to the industry distribution chart, Artelo Biosciences ranks #511 out of 1103 companies in the Biotechnology industry, placing it in the top 46.3%.
Is Artelo Biosciences' 3-Year FCF Growth Rate too high?
Artelo Biosciences' current 3-Year FCF Growth Rate of 21.90% is near median its 10-year median of 21.90. The Biotechnology industry median 3-Year FCF Growth Rate is 19.40. Artelo Biosciences' value of 21.90% is 12.9% above this industry median. Based on the distribution chart, Artelo Biosciences ranks #511 out of 1103 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' 3-Year FCF Growth Rate compare to PPCB and CLDI?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #511 out of 1103 companies for 3-Year FCF Growth Rate. This puts Artelo Biosciences in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 19.40. Artelo Biosciences' value of 21.90% is 12.9% above this benchmark. While the company's 10-year median is 21.90 vs. the industry median of 19.40, Artelo Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.40, based on 1,103 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current 3-Year FCF Growth Rate of 21.90% is 12.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Artelo Biosciences and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current 3-Year FCF Growth Rate is 21.90%, which is near median its own 10-year median of 21.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current 3-Year FCF Growth Rate of 21.90%. The current 3-Year FCF Growth Rate is 21.90%, which is near median its 10-year median of 21.90 and 12.9% above the Biotechnology industry median of 19.40. Artelo Biosciences' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current 3-Year FCF Growth Rate is 21.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
32GF Score
Get the complete analysis for ARTL
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
